Published September 2021
| Version v1
Journal article
A Multi-Institutional Phase 2 Trial of High-Dose SAbR for Prostate Cancer Using Rectal Spacer
Creators
- 1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York (United States)
- 2. Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas (United States)
- 3. Department of Urology, University of Texas Southwestern Medical Center, Dallas (United States)
Description
High-dose SABR for prostate cancer offers the radiobiologic potency of the most intensified radiation therapy regimens but was associated with >90% rates of ulceration of the anterior rectal wall on endoscopic assessment; this infrequently progressed to severe rectal toxicity in prior prospective series. A multi-institutional phase 2 prospective trial was conducted to assess whether placement of a perirectal hydrogel spacer would reduce acute periprostatic rectal ulcer events after high-dose (>40 Gy) SABR.
Availability note (English)
Available from http://dx.doi.org/10.1016/j.ijrobp.2021.03.025Additional details
Identifiers
- DOI
- 10.1016/j.ijrobp.2021.03.025;
- PII
- S0360301621002856;
Publishing Information
- Journal Title
- International Journal of Radiation Oncology, Biology and Physics
- Journal Volume
- 111
- Journal Issue
- 1
- Journal Page Range
- p. 101-109
- ISSN
- 0360-3016
- CODEN
- IOBPD3
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 53122352
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- HYDROGELS; NEOPLASMS; PROSTATE; RADIATION DOSES; RADIOTHERAPY; RECTUM; TOXICITY
- Descriptors DEC
- BODY; COLLOIDS; DIGESTIVE SYSTEM; DISEASES; DISPERSIONS; DOSES; GASTROINTESTINAL TRACT; GELS; GLANDS; INTESTINES; LARGE INTESTINE; MALE GENITALS; MEDICINE; NUCLEAR MEDICINE; ORGANS; RADIOLOGY; THERAPY
Optional Information
- Copyright
- Copyright (c) 2021 Elsevier Inc. All rights reserved.